Endometrial Clear Cell Adenocarcinoma

general

A high-grade endometrial adenocarcinoma characterized by the presence of large neoplastic cells that display at least focal cytoplasmic clearing. The neoplastic cells form papillary, glandular, or sheet-like structures.

81

Centers

255

Active Trials

$10M

Cancer Funding

Specific Cancer Types(1)

Top Centers for Endometrial Clear Cell Adenocarcinoma(81)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
172.6
2
High-Volume Research Center
72.6
3
NCI Comprehensive
Active Research Program
68.6
4
NCI Comprehensive
Active Research Program
68.6
5
NCI Comprehensive
Active Research Program
68.6
6
NCI Comprehensive
Active Research Program
68.6
7
NCI Clinical
Active Research Program
68.6
8
NCI Comprehensive
Active Research Program
68.6
9
Active Research Program
68.6
10
NCI Comprehensive
Active Research Program
68.6
11
NCI Clinical
Active Research Program
68.6
12
NCI Comprehensive
Active Research Program
68.6
13
Active Research Program
68.6
14
Active Research Program
68.6
15
Active Research Program
60.2
16
NCI Comprehensive
Active Research Program
60.2
17
NCI Comprehensive
Active Research Program
60.2
18
NCI Comprehensive
Active Research Program
60.2
19
NCI Comprehensive
Active Research Program
60.2
20
NCI Comprehensive
Active Research Program
60.2
21
NCI Comprehensive
Active Research Program
60.2
22
NCI Comprehensive
Active Research Program
60.2
23
NCI Comprehensive
Active Research Program
60.2
24
NCI Comprehensive
Active Research Program
60.2
25
NCI Comprehensive
Active Research Program
60.2
26
Active Research Program
60.2
27
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
Active Research Program
60.2
28
NCI Clinical
Active Research Program
60.2
2960.2
30
Active Research Program
60.2
31
Active Research Program
60.2
32
Active Research Program
60.2
33
NCI Comprehensive
Active Research Program
47.2
34
NCI Comprehensive
Active Research Program
47.2
35
NCI Comprehensive
Active Research Program
47.2
36
NCI Comprehensive
Active Research Program
47.2
37
NCI Comprehensive
Active Research Program
47.2
38
NCI Comprehensive
Active Research Program
47.2
39
NCI Comprehensive
Active Research Program
47.2
40
NCI Comprehensive
Active Research Program
47.2
41
NCI Comprehensive
Active Research Program
47.2
42
NCI Comprehensive
Active Research Program
47.2
43
NCI Comprehensive
Active Research Program
47.2
44
NCI Comprehensive
Active Research Program
47.2
45
NCI Comprehensive
Active Research Program
47.2
46
NCI Comprehensive
Active Research Program
47.2
47
Active Research Program
47.2
48
NCI Clinical
Active Research Program
47.2
49
NCI Comprehensive
Active Research Program
47.2
50
NCI Comprehensive
Active Research Program
47.2
51
NCI Comprehensive
Active Research Program
47.2
52
Active Research Program
47.2
53
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
Active Research Program
47.2
54
Active Research Program
47.2
55
Active Research Program
47.2
56
Active Research Program
47.2
57
Active Research Program
47.2
5847.2
59
Active Research Program
47.2
60
Active Research Program
47.2
61
NCI Comprehensive
Contributing Research Center
34.9
62
NCI Comprehensive
Contributing Research Center
34.9
63
NCI Comprehensive
Contributing Research Center
34.9
64
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
Contributing Research Center
34.9
65
NCI Comprehensive
Contributing Research Center
34.9
66
NCI Comprehensive
Contributing Research Center
34.9
67
NCI Comprehensive
Contributing Research Center
34.9
68
Cedars-Sinai CancerLos Angeles, CA
Contributing Research Center
34.9
69
NCI Comprehensive
Contributing Research Center
34.9
70
Contributing Research Center
34.9
71
NCI Comprehensive
Contributing Research Center
34.9
72
Contributing Research Center
34.9
73
Contributing Research Center
34.9
74
Contributing Research Center
34.9
75
Contributing Research Center
34.9
76
Contributing Research Center
34.9
7729.2
78
NCI Clinical
29.2
79
Stephenson Cancer CenterOklahoma City, OK
NCI Clinical
29.2
80
NCI Basic_laboratory
29.2
81

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →